Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556788 · ClinicalTrials.gov registry record · Phase 3
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,212
- Enrollment target
NCT02556788: Completed Phase 3 study, sponsored by Galderma R&D.
NCT02556788 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 1,212 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02556788, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,212 participants
- Enrollment target
Study Summary
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Primary Outcome
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
Interventions
- DRUG Placebo Cream
- DRUG CD5789 (trifarotene) 50µg/g Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,212 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05-12 |
| Phase | Phase 3 |
What the finished NCT02556788 record still lists
NCT02556788 is an interventional study that assigns participants to a tested intervention. Its 1,212 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo Cream is the first listed.
NCT02556788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02556788 about?
NCT02556788 is a clinical study titled "Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris". Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
What is the current status of trial NCT02556788?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,212 participants. The study started on 2015-11. Estimated completion is 2017-05-12.
What interventions are being tested in trial NCT02556788?
The interventions under investigation include: Placebo Cream (DRUG), CD5789 (trifarotene) 50µg/g Cream (DRUG).
Who is sponsoring clinical trial NCT02556788?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02556788's enrollment target sits among peer trials
1,212 216th of 2000 higher than 1,785 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia